CYP2D6 and Tamoxifen: Awaiting the Denouement Reply

被引：0

作者：

Rae, James M. ^{[1
]}

机构：

[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 34期

关键词：

PHARMACOGENETICS; METABOLITE;

D O I：

10.1200/JCO.2011.39.0971

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：4590 / 4591

页数：3

共 50 条

[21] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors [J].

Gressier, F. ;

Verstuyft, C. ;

Hardy, P. ;

Becquemont, L. ;

Corruble, E. .

JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) :35-42

[22] Impact of CYP2D6 Polymorphisms on the Efficacy of Tamoxifen in Iraqi Women With Breast Cancer [J].

Ali, Sura S. Abid ;

Sahib, Ahmed S. ;

Abdulamir, Ahmed S. ;

Kadhim, Haitham M. .

JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (06) :436-448

[23] CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer [J].

He, Wei ;

Grassmann, Felix ;

Eriksson, Mikael ;

Eliasson, Erik ;

Margolin, Sara ;

Thoren, Linda ;

Hall, Per ;

Czene, Kamila .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) :548-+

[24] Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping [J].

Binkhorst, Lisette ;

Mathijssen, Ron H. J. ;

Jager, Agnes ;

van Gelder, Teun .

CANCER TREATMENT REVIEWS, 2015, 41 (03) :289-299

[25] Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio [J].

Lee, Clara Inkyung ;

Low, Siew Kee ;

Maldonado, Ricardo ;

Fox, Peter ;

Balakrishnar, Bavanthi ;

Coulter, Sally ;

de Bruijn, Peter ;

Koolen, Stijn L. W. ;

Gao, Bo ;

Lynch, Jodi ;

Zdenkowski, Nicholas ;

Hui, Rina ;

Liddle, Christopher ;

Mathijssen, Ron H. J. ;

Wilcken, Nicholas ;

Wong, Mark ;

Gurney, Howard .

BREAST, 2020, 54 :229-234

[26] Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy [J].

Goetz, Matthew P. ;

Ratain, Mark ;

Ingle, James N. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) :3944-+

[27] CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients [J].

Barriere, J. ;

Formento, J. -L. ;

Milano, G. ;

Ferrero, J. -M. .

BULLETIN DU CANCER, 2010, 97 (03) :311-320

[28] CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial [J].

V. O. Dezentjé ;

R. H. N. van Schaik ;

J. M. Vletter-Bogaartz ;

T. van der Straaten ;

J. A. M. Wessels ;

E. M.-K. Kranenbarg ;

E. M. Berns ;

C. Seynaeve ;

H. Putter ;

C. J. H. van de Velde ;

J. W. R. Nortier ;

H. Gelderblom ;

H.-J. Guchelaar .

Breast Cancer Research and Treatment, 2013, 140 :363-373

[29] Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene [J].

Novillo, A. ;

Romero-Lorca, A. ;

Gaibar, M. ;

Rubio, M. ;

Fernandez-Santander, A. .

PHARMACOGENOMICS JOURNAL, 2017, 17 (02) :109-111

[30] CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned [J].

Kelly, Catherine M. ;

Pritchard, Kathleen I. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06) :427-428

← 1 2 3 4 5 →